1,070 results on '"Ohashi, Pamela S."'
Search Results
2. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient
3. Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-β1 and IL-2 confer immunoregulatory functions to NK cells
4. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
5. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire
6. PD-1 regulates ILC3-driven intestinal immunity and homeostasis
7. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
8. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
9. Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer
10. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity
11. TREM-2 mediates dendritic cell–induced NO to suppress Th17 activation and ameliorate chronic kidney diseases
12. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
13. Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization
14. Coenzyme A fuels T cell anti-tumor immunity
15. A distinct innate lymphoid cell population regulates tumor-associated T cells
16. Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
17. Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial
18. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
19. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
20. Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells
21. Rational design and identification of immuno-oncology drug combinations
22. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
23. A Critical Role for the Innate Immune Signaling Molecule IRAK-4 in T Cell Activation
24. Defining the Critical Hurdles in Cancer Immunotherapy
25. Costimulation, a surprising connection for immunotherapy
26. B Cells Promote T Cell Immunosenescence and Mammalian Aging Parameters
27. Positive Regulation of T Cell Activation and Integrin Adhesion by the Adapter Fyb/Slap
28. Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy
29. Regulation of T Cell Activation, Anxiety, and Male Aggression by RGS2
30. Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches
31. Function of PI3Kγ in Thymocyte Development, T Cell Activation, and Neutrophil Migration
32. Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
33. Supplementary Table S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
34. Suppl Figure S1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
35. Data from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
36. A novel population of CD103-expressing CD56 +regulatory ILCs suppresses intratumoural T cells and are associated with poor prognosis in patients with ovarian carcinoma
37. Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
38. Table S2 from Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer
39. Data from Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer
40. Abstract 3651: The role of caspase-1 in basal-like breast cancer and the tumor microenvironment
41. Data from IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function
42. Data from Overproduction of IFNγ by Cbl-b–Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity
43. Supplementary Figures from Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer
44. Supplementary Figure from Overproduction of IFNγ by Cbl-b–Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity
45. Abstract 6667: Pan-cancer assessment of tumour and peripheral T-cell receptor repertoire dynamics in patients treated with immune checkpoint inhibitors
46. Supplementary Figures and Tables from IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function
47. Data from Notch Shapes the Innate Immunophenotype in Breast Cancer
48. Data from Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
49. SupplementalTables from Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
50. Supplementary Figures 1 - 7 from B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.